Industry Trends

Oncology and rare disease are ready to reap the benefits of COVID drug development.

Growing evidence supports psychoactive substances can successfully treat mental issues.

As borders shut down during the pandemic, pharma learned some lessons about sourcing.

Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future.

Ahead of the release of EY’s annual M&A Firepower report this week, Pharm Exec talks to EY’s Arda Ural to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.

As big tech’s healthcare disruption efforts flag, biopharma can step up to empower patients and improve care, writes Rohit Gupta.

Patient protection and social influence among trends to look out for as calendar turns.

Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.

On December 22, 2021, FDA authorized emergency use of Pfizer’s oral antiviral drug Paxlovid on December 22, 2021, skipping the advisory committee review to make the drug available as quickly as possible. The following day, FDA provided similar authorization for Merck’s Molnupiravir.

Practices to ensure accuracy in selected datasets.

While pharma has reached new heights in vaccine development, many questions remain around the lasting effects of COVID and how future therapies can curb them.

It wasn’t long before sales reps realized they needed a new strategy to keep prospect pools flowing—18 months later, a mix of in-person and virtual meetings with healthcare professionals is emerging as the preferred approach moving forward.

Pharma organizations have long been vigilant in protecting their intellectual property and financial information, but the disruption of COVID-19 has seen an expansion of the ‘cyberattack surface.’

How an increased focus on people has helped companies survive the pandemic.

Having proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer.

Changes prompt collaboration and improved quality management.

Open Orphan CEO Cathal Friel talks to Pharm Exec about how the company is distinctive from traditional CROs and its role in the UK’s COVID-19 human challenge study.

Lorna Meldrum, Vice President, Commercial Operations, International Markets & Pandemic at Seqirus, talks about the challenges of the influenza vaccine market and how COVID-19 has highlighted that preventing ’flu is crucial for public health.

Dr. Shankar Musunuri talks about his 25 years’ experience in biotech about his company Ocugen’s latest mission to develop, manufacture, and commercialize Bharat Biotech’s COVID-19 vaccine, COVAXIN, in the North American market.

If the debate over vaccines for adults and the need for extra booster shots has been heated, FDA will face even more scrutiny over the safety and value of vaccinating children under age 12.

FDA’s Vaccines and Related Biological Products Advisory Committee announces its recommendations for the authorization of a third dose of the Pfizer/BioNTech Comirnaty vaccine.

Life sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.

White House officials recently announced a nearly $3 billion program to ramp up production of vaccines and their components to better serve patients in the U.S. and globally.

Using the interview process to ensure high organizational standards.

Sy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.

FDA has granted full approval for the Pfizer/BioNTech anti-COVID 19 vaccine, raising hopes that this action will help overcome the vaccine hesitancy that has plagued efforts to broadly immunize the U.S. population.

Rory Mullen outlines Ireland’s importance to multinational pharma in the changing EU landscape.

All eyes are watching closely to see how well Viatris and Biocon Biologics’ Semglee, approved by FDA on July 28, competes with Sanofi’s well-established, long-acting insulin analog, Lantus.

Changes necessitated by COVID will drive unprecedented transformation of industry.

COVID-19 may be the latest challenge to primary care physicians, but it’s just one of many threatening the profession, including the increased focus on specialty drug markets—if PCPs are left out of the equation.